Basilea Announces Submission of Marketing Authorization Application in Europe by Janssen-Cilag International NV for Ceftobiprole

19-Jun-2007

Basilea Pharmaceutica Ltd. announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for ceftobiprole by its license partner Janssen-Cilag International NV, a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections. according to the company, Ceftobiprole is the first anti-MRSA broad-spectrum cephalosporin antibiotic to complete Phase III clinical trials.

This Marketing Authorization Application (MAA) of ceftobiprole for the treatment of complicated skin and soft tissue infections includes the data from two pivotal phase III trials (STRAUSS 1 and STRAUSS 2). These trials comprise data from over 1600 patients including those with diabetic foot infections caused by Gram-negative, Gram-positive and methicillin-resistant Staphylococcus aureus (MRSA) pathogens. In both multinational, double-blind, randomized phase III studies, ceftobiprole achieved a high clinical cure rate compared to single drug or two-drug combination comparators, respectively. Ceftobiprole was well tolerated with a safety profile consistent with the cephalosporin class of antibiotics.

A milestone payment of approximately CHF 12 million is associated with the MAA filing acceptance.

Ceftobiprole is currently in clinical phase III testing in hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) and in hospitalized patients with community-acquired pneumonia (CAP) with anticipated completion in the second half of the year.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...